Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
Type:
Grant
Filed:
September 2, 1999
Date of Patent:
February 20, 2001
Assignee:
Xoma Corporation
Inventors:
Nadav Friedmann, Patrick J. Scannon, Sander J. H. van Deventer, Marijke A. M. von der Mohlen, Nancy Wedel
Abstract: The present invention relates to methods for treating chlamydial infection comprising administering to a subject suffering from a chlamydial infection a bactericidal/permeability-inducing (BPI) protein product.
Abstract: The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and in vivo or in vitro uses of such peptides.
Type:
Grant
Filed:
January 8, 1999
Date of Patent:
December 5, 2000
Assignee:
Xoma Corporation
Inventors:
Roger G. Little, II, Edward Lim, Mitchell B. Fadem
Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
Type:
Grant
Filed:
April 15, 1997
Date of Patent:
November 14, 2000
Assignee:
Xoma Corporation
Inventors:
Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
Abstract: The present invention relates to methods and compositions for treating gram-negative bacterial infections, using BPI protein products. Co-treatment, or concurrent administration, of BPI protein product with an antibiotic in treatment of gram-negative bacterial infections improves the therapeutic effectiveness of the antibiotic, including increasing antibiotic susceptibility of gram-negative bacteria and reversing resistance of the bacteria to antibiotics.
Type:
Grant
Filed:
June 3, 1996
Date of Patent:
October 31, 2000
Assignee:
Xoma Corporation
Inventors:
Lewis H. Lambert, Jr., Roger G. Little, II
Abstract: Antithrombotic materials and methods are provided for the treatment of thrombotic disorders, in which therapeutically effective amounts of BPI protein products are administered.
Abstract: Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides encoding these products, materials and methods for their recombinant production, compositions and medicaments of these products, and therapeutic uses for these products.
Type:
Grant
Filed:
June 18, 1999
Date of Patent:
July 11, 2000
Assignee:
XOMA Corporation
Inventors:
Arnold Horwitz, Stephen F. Carroll, David Burke
Abstract: Polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising a polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate surfactants. Preferred polypeptides stabilized are bactericidal/permeability increasing (BPI) protein, biologically active fragments of BPI, biologically active analogs of BPI, and biologically active variants of BPI.
Type:
Grant
Filed:
May 17, 1999
Date of Patent:
May 23, 2000
Assignee:
Xoma Corporation
Inventors:
Weldon Courtney McGregor, James Stubstad, C. Paul Chang
Abstract: Bactericidal/permeability increasing protein (BPI) and biologically active fragments, analogs and variants thereof are solubilized by lipid carriers including phospholipids, liposomes and nonionic detergents and stabilized against particle formation by poloxamer surfactants.
Abstract: The present invention relates to methods of treating gram-positive bacterial infections by administration of a BPI protein product alone, or in combination with an antibiotic. BPI protein product alone has a bactericidal or growth inhibitory effect on selected gram-positive organisms. BPI protein product also increases the susceptibility of gram-positive organisms to antibiotics and can even reverse resistance of gram-positive organisms to antibiotic.
Type:
Grant
Filed:
July 20, 1998
Date of Patent:
April 25, 2000
Assignee:
XOMA Corporation
Inventors:
Arnold Horwitz, Lewis H. Lambert, Jr., Roger G. Little, II
Abstract: The present invention provides methods of potentiating the gram-negative bactericidal activity of BPI protein products by means of administering LBP protein products.
Abstract: The present invention provides methods of treating adverse physiological effects associated with intestinal ischemia/reperfusion by administering to a subject suffering from the effects of intestinal ischemia/reperfusion an effective amount of a BPI protein product.
Type:
Grant
Filed:
November 25, 1996
Date of Patent:
January 25, 2000
Assignee:
XOMA Corporation
Inventors:
William Steve Ammons, Karoly M. Meszaros
Abstract: The present invention relates to methods for treating protozoan infections comprising administering to a subject suffering from protozoan infection, a bacteriocidal/permeability-inducing (BPI) protein product.
Abstract: Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides encoding these products, materials and methods for their recombinant production, compositions and medicaments of these products, and therapeutic uses for these products.
Type:
Grant
Filed:
June 19, 1998
Date of Patent:
January 11, 2000
Assignee:
XOMA Corporation
Inventors:
Arnold Horwitz, Stephen Fitzhugh Carroll, David Burke
Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
Abstract: Polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising a polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate surfactants. Preferred polypeptides stabilized are bactericidal/permeability increasing (BPI) protein, biologically active fragments of BPI, biologically active analogs of BPI, and biologically active variants of BPI.
Type:
Grant
Filed:
December 8, 1997
Date of Patent:
September 21, 1999
Assignee:
XOMA Corporation
Inventors:
Weldon Courtney McGregor, James Stubstad, C. Paul Chang
Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
Type:
Grant
Filed:
May 18, 1998
Date of Patent:
September 14, 1999
Assignee:
Xoma Corporation
Inventors:
Nadav Friedmann, Patrick J. Scannon, Sander J.H. van Deventer, Marijke A.M. von der Mohlen, Nancy Wedel